Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03872778 · ClinicalTrials.gov registry record · Phase 1
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
A Phase 1 study of Neoplasms, sponsored by Advanced Accelerator Applications.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 11
- Study locations
NCT03872778 is a Phase 1 study of Neoplasms that has completed, run by Advanced Accelerator Applications. The registered enrollment target is 35 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The trial reports 11 study locations across 6 states.
The verdict
NCT03872778, a Phase 1 study of Neoplasms, has completed, sponsored by Advanced Accelerator Applications.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 11
- Study locations
Study Summary
First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of \[177Lu\]-NeoB in patients with advanced solid tumors known to overexpress GRPR and with \[68Ga\]-NeoB lesion uptake.
Conditions Studied
Interventions
- DRUG LCZ696
- DRUG [177Lu]-NeoB
- DRUG [68Ga]-NeoB
Study Locations (11)
Other
- Medical University of Innsbruck - Innsbruck
- CHU de Grenoble - La Tronche
- Erasmus MC - Rotterdam
- Vall d'Hebron Institute of Oncology - Barcelona
- Addenbroke's hospital - Cambridge
California
- City of Hope - Duarte
- Stanford University - Stanford
Maryland
- John Hopkins University - Baltimore
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- Pittsburgh University - Pittsburgh
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-05-24 |
| Est. Completion | 2025-11-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03872778
The ClinicalTrials.gov registry entry for NCT03872778 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (98% lower). The listed sponsor is Advanced Accelerator Applications, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which LCZ696 is the first listed.
NCT03872778 reports 11 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT03872778 about?
NCT03872778 is a clinical study titled "[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake". First in Human (FIH) study to characterize the safety, tolerability, pharmacokinetics (PK), distribution, radiation dosimetry, and anti-tumor activity of \[177Lu\]-NeoB in patients with advanced solid tumors known to overexpress GRPR and with \[68Ga\]-NeoB lesion uptake.
What is the current status of trial NCT03872778?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-05-24. Estimated completion is 2025-11-27.
What conditions does trial NCT03872778 study?
This clinical trial studies the following conditions: Neoplasms.
What interventions are being tested in trial NCT03872778?
The interventions under investigation include: LCZ696 (DRUG), [177Lu]-NeoB (DRUG), [68Ga]-NeoB (DRUG).
Who is sponsoring clinical trial NCT03872778?
This trial is sponsored by Advanced Accelerator Applications, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03872778 being conducted?
This trial has 11 study locations across California, Maryland, Oregon, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.